NCT04246671: Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least one prior line of disease-appropriate therapy for locally advanced or metastatic disease
Exclusions: Patients with known untreated unstable metastatic disease to the central nervous system – see trial for details

Comments are closed.

Up ↑